Skip to main content

Advertisement

SpringerLink
Log in

Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials

  • Mini Review
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The standard treatment of CRC patients with hepatic metastases is systemic chemotherapy; however, 5-year survival is disappointingly poor despite recent advances. On the other hand, in patients who undergo immediate radical surgical resection of hepatic metastases, 5-year survival reaches 30–40%. Unfortunately, only 15–20% of patients with hepatic metastases are initially eligible for a radical surgical approach. The majority of patients undergoing liver resection relapse after surgery. For this reason, new onco-surgery approaches have been investigated in recent years and the addition of biological agents to chemotherapy, such as bevacizumab and cetuximab, and the improvements of surgical techniques have opened a new scenario in the management of colorectal liver metastases. Recently, the EORTC trial has demonstrated that perioperative chemotherapy (Folfox regimen) is feasible and improves progression-free survival in patients with resectable liver metatsases. Chemotherapy and surgery can finally collaborate. In the unresectable setting, the association of chemotherapy with bevacizumab and cetuximab is particularly promising in improving resectability rate. In particular, K-RAS is a molecular response predictive factor that could be particularly useful in selecting the best treatment option in patients with unresectable liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonadonna G, Robustelli della Cuna G, Valagussa P (2009) Medicina Oncologica VII

  2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al (2004) Cancer statistics. CA Cancer J Clin 54:8–29

    Article  PubMed  Google Scholar 

  3. Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. World J Surg 19:59–71

    Article  CAS  PubMed  Google Scholar 

  4. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522

    Article  CAS  PubMed  Google Scholar 

  5. Adson MA (1987) Resection of liver metastases: when is it worthwhile? World J Surg 11:511–520

    Article  CAS  PubMed  Google Scholar 

  6. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946

    CAS  PubMed  Google Scholar 

  7. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K et al (2003) Therapeutic results of hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46:22–31

    Google Scholar 

  8. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016

    Article  CAS  PubMed  Google Scholar 

  9. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J et al (1986) Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73:727–731

    Article  CAS  PubMed  Google Scholar 

  10. Poston G, Haller D, Kahan J, Cornelis M, Mahyaoui S (2004) Individualize the treatment of liver metastases from colorectal cancer using RAND appropriateness method: oncosurge decision model-results of a consensus detecting from the international task force group. J Clin Oncol 22 (abstr 3595)

  11. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al (1996) Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77:1254–1262

    Article  CAS  PubMed  Google Scholar 

  12. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189:291–299

    Article  CAS  PubMed  Google Scholar 

  13. Adam V, Delvart G, Pascal D, Castaing D, Azoulay S, Giachetti B et al (2004) Resection of non resectable liver metastases after chemotherapy: prognostic factors and long-term results. J Clin Oncol 22 (abstr 3550)

  14. Mala T, Bohler G, Mathisen O, Bergan A, Søreide O (2002) Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg 26:1348–1353

    Article  PubMed  Google Scholar 

  15. Quispe IR, Ramos FJ, Bilbao I, Macarulla T, Cedres S, Charco R et al (2009) Long-term overall survival (os) and prognostic factors of patients (pts) with surgery of liver metastases from colorectal cancer origin (lm/crc): Retrospective analysis of a Spanish single institution. J Clin Oncol 27 (abstr 15052)

  16. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22:229–237

    Article  CAS  PubMed  Google Scholar 

  17. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK et al (2004) A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  CAS  PubMed  Google Scholar 

  18. Falcone A, Ricci S, Brunett I, Pfanner E, Allegrini G, Barbara C et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676

    Article  CAS  PubMed  Google Scholar 

  19. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal (liver) metastases. Ann Surg Oncol 8:347–353

    Article  CAS  PubMed  Google Scholar 

  20. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663–669

    Article  CAS  PubMed  Google Scholar 

  21. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835

    Article  PubMed  Google Scholar 

  22. Alberts SR, Donohue JH, Mahoney MR, Horvath WL, Sternfeld WC, Dakhil SR et al (2003) Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: a north central cancer treatment group (NCCTG) phase II study. J Clin Oncol 22 (abstr 1053)

  23. Quenet F, Nordlinger B, Rivoire M, Delpero JR, Portier G, Mery-Mignard D et al (2004) Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) afer chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial. J Clin Oncol 22 (abstr 3613)

  24. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N et al (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933–939

    Article  CAS  PubMed  Google Scholar 

  25. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945

    Article  PubMed  Google Scholar 

  26. Gruenberger T, Schuell B, Kornek G, Scheithauer W (2004) Neoadjuvant chemotherapy for resectable colorectal cancer liver metastasis: impact on magnitude of liver resection and survival. J Clin Oncol 22 (abstr 3598)

  27. Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T et al (2005) Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 23:502–509

    Google Scholar 

  28. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072

    Article  CAS  PubMed  Google Scholar 

  29. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853

    Article  PubMed  Google Scholar 

  30. Adam R, Sebagh M, Plasse M, Karam V, Giachetti S, Azoulay D et al (2005) Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM). J Clin Oncol 23 (abstr 3529)

  31. Wicherts DA, De Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B et al (2009) Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases. J Clin Oncol 27 (abstr 4097)

  32. Nordlinger B, Benoist S (2006) Benefits risks of neoadjuvant therapy for liver metastases. J Clin Oncol 24:4954–4955

    Article  PubMed  Google Scholar 

  33. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  34. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of Bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–3712

    Article  CAS  PubMed  Google Scholar 

  35. Giantonio BJ, Catalano PJ, Meropol NJ, Mitchell EP, Schwartz MA, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  36. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173–180

    Article  CAS  PubMed  Google Scholar 

  37. Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastases in the era of bevacizumab. J Clin Oncol 23:4853–4855

    Article  CAS  PubMed  Google Scholar 

  38. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F et al (2008) Bevacizumab, Capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metatsatic colorectal cancer. J Clin Oncol 26:1830–1835

    Article  CAS  PubMed  Google Scholar 

  39. Michael M, Van Cutsem E, Kretzschmar A, Berry S, Rivera F, Dibartolomeo M et al (2006) Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC: preliminary results from the First Beat-study. J Clin Oncol 24 (abstr 3523)

  40. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  PubMed  Google Scholar 

  41. Bouganim N, Kavan P, Eid M, Metrakos P, Chaudhury P, Batist G (2009) Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. J Clin Oncol 27 (abstr e15027)

  42. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35:515–520

    CAS  PubMed  Google Scholar 

  43. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593–4602

    Article  CAS  PubMed  Google Scholar 

  44. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT et al (2010) Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

    Google Scholar 

  45. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  46. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  CAS  PubMed  Google Scholar 

  47. Garufi C, Torsello A, Tumolo S, Mottolese M, Campanella C, Zeuli M et al (2009) POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 27 (abstr e15020)

Download references

Author information

Authors and Affiliations

  1. Department of Colorectal Medical Oncology, National Cancer Institute of Naples, via M. Semmola, 80131, Naples, Italy

    G. Nasti, A. Ottaiano, A. Cassata, C. Romano, G. Facchini, F. Perri & R. V. Iaffaioli

  2. Department of Medical Oncology, National Cancer Institute of Aviano, Aviano, Italy

    M. Berretta

  3. Colorectal Department, Surgery Unit, National Cancer Institute of Naples, Naples, Italy

    P. Delrio, D. Scala & G. Romano

  4. Epato-Biliary Department, Surgery Unit, National Cancer Institute of Naples, Naples, Italy

    F. Izzo & A. Mastro

Authors
  1. G. Nasti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Ottaiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Berretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Delrio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Izzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Cassata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Facchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Scala
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Mastro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. Perri
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R. V. Iaffaioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Nasti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nasti, G., Ottaiano, A., Berretta, M. et al. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol 66, 209–218 (2010). https://doi.org/10.1007/s00280-010-1297-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1297-x

Keywords

Search

Navigation